Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective …
…, M McKean, KE Beckermann, SM Rubinstein… - The Lancet …, 2018 - thelancet.com
Background Obesity has been linked to increased mortality in several cancer types; however,
the relation between obesity and survival outcomes in metastatic melanoma is unknown. …
the relation between obesity and survival outcomes in metastatic melanoma is unknown. …
Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19
Importance COVID-19 is a life-threatening illness for many patients. Prior studies have
established hematologic cancers as a risk factor associated with particularly poor outcomes from …
established hematologic cancers as a risk factor associated with particularly poor outcomes from …
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study
Evaluating the potential role of COVID-19 treatments in patients with cancer in a large
observational study, there was no statistically significant 30-day all-cause mortality benefit with …
observational study, there was no statistically significant 30-day all-cause mortality benefit with …
Impact of age on outcomes with immunotherapy for patients with melanoma
…, RAN Johnpulle, K Rubin, SM Rubinstein… - The …, 2017 - academic.oup.com
Background Monoclonal antibodies (mAb) targeting PD‐1/PD‐L1 have revolutionized melanoma
treatment, yet data regarding effectiveness and tolerability across age groups is limited…
treatment, yet data regarding effectiveness and tolerability across age groups is limited…
The evolving use of electronic health records (EHR) for research
E Kim, SM Rubinstein, KT Nead… - Seminars in radiation …, 2019 - Elsevier
Electronic health records (EHR) have been implemented successfully in a majority of United
States healthcare systems in some form. There has been a rise in secondary uses of EHR, …
States healthcare systems in some form. There has been a rise in secondary uses of EHR, …
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study …
…, TK Nonato, R Quinn, SM Rubinstein, M Puc… - The Lancet Regional …, 2023 - thelancet.com
Background Breakthrough SARS-CoV-2 infections following vaccination against COVID-19
are of international concern. Patients with cancer have been observed to have worse …
are of international concern. Patients with cancer have been observed to have worse …
[PDF][PDF] The COVID-19 and cancer consortium: a collaborative effort to understand the effects of COVID-19 on patients with cancer
National and international consortia will play a key role in understanding the effects of the
coronavirus disease 2019 (COVID-19) pandemic on cancer patients. The COVID-19 and …
coronavirus disease 2019 (COVID-19) pandemic on cancer patients. The COVID-19 and …
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents
…, M Jagasia, S Harrell, SM Rubinstein… - British journal of …, 2020 - Wiley Online Library
Immunomodulatory drugs (IMiDs) have improved survival of patients with multiple myeloma (MM)
and comprise the therapeutic backbone at all phases of therapy. Although well‐…
and comprise the therapeutic backbone at all phases of therapy. Although well‐…
[HTML][HTML] Immune-mediated complications after hematopoietic stem cell transplantation
Z Li, SM Rubinstein, R Thota, M Savani… - Biology of Blood and …, 2016 - Elsevier
… Author links open overlay panel Zhuoyan Li 1 , Samuel M. Rubinstein 1 , Ramya Thota 2
, Malvi Savani 3 , Eolia Brissot 4 5 6 , Bronwen E. Shaw 7 , Navneet S. Majhail 8 , Mohamad …
, Malvi Savani 3 , Eolia Brissot 4 5 6 , Bronwen E. Shaw 7 , Navneet S. Majhail 8 , Mohamad …
